Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: Comment on the article by Charles et al
Open Access
- 7 August 2001
- journal article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 44 (8) , 1966-1968
- https://doi.org/10.1002/1529-0131(200108)44:8<1966::aid-art339>3.0.co;2-3
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Infliximab-Associated Reversible Cholestatic Liver DiseaseMayo Clinic Proceedings, 2001
- Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trialsArthritis & Rheumatism, 2000
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999